Orthofix names new CEO and CFO; Q4 net sales $200.3M, pro forma up 7.5%

Orthofix Medical Inc.

Massimo Calafiore appointed CEO, effective Jan 8, 2024; received $7.5M in inducement equity awards (RSUs + options).
Julie Andrews named CFO, effective Jan 15; base salary $475K, target bonus 70%, sign-on equity $1.8M.
Kevin Kenny departed as officer Jan 8; eligible for severance and $500/hr consulting for 12 months.
Q4 preliminary net sales $200.3M, +63.8% reported (+7.5% pro forma); BGT up 15.3%.
Full-year 2023 net sales $746.5M, +62% reported (+6.5% pro forma).

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Julie Andrews

Chief Financial Officer

OFIX · Orthofix Medical Inc.

Effective: 2024-01-15
Filed: January 9, 2024, 6:59 PM ET

the Board appointed Julie Andrews as the Company’s Chief Financial Officer, effective as of January 15, 2024

Appointed

Massimo Calafiore

President and Chief Executive Officer

OFIX · Orthofix Medical Inc.

Effective: 2024-01-08
Filed: January 9, 2024, 6:59 PM ET

the Company’s Board of Directors (the “Board”) appointed Massimo Calafiore as the Company’s President and Chief Executive Officer, and Mr. Calafiore began service on such date.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Orthofix Medical Inc. reported the fiscal quarter and year ended December 31, 2023 results: revenue $200.3 million.

Period: the fiscal quarter and year ended December 31, 2023
Revenue: $200.3 million
Result: preliminary results

Exact text from the filing

Net sales of $200.3 million, an increase of 64% on a reported basis and an increase of 8% on a pro forma basis

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Julie Andrews was appointed as Chief Financial Officer at Orthofix Medical Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

the Board appointed Julie Andrews as the Company’s Chief Financial Officer, effective as of January 15, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Massimo Calafiore was appointed as President and Chief Executive Officer at Orthofix Medical Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

the Company’s Board of Directors (the “Board”) appointed Massimo Calafiore as the Company’s President and Chief Executive Officer, and Mr. Calafiore began service on such date.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Orthofix Medical Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-003420

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.